Sign up to save your podcasts
Or
Share FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Colorectal Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Colorectal Cancer
Explore the latest breakthroughs in treating MSI-H/dMMR metastatic colorectal cancer with immune therapies! This episode dives into the exciting world of immune checkpoint inhibitors (ICIs) like nivolumab (Opdivo) and ipilimumab (Yervoy), highlighting their significant clinical benefits for this specific patient population. Learn about the molecular characteristics of MSI-H/dMMR CRC that make it uniquely sensitive to immunotherapy. Our AI hosts will cover pivotal clinical trials, including CheckMate 8HW, which demonstrated the improved progression-free survival with the combination of nivolumab and ipilimumab compared to nivolumab alone. Discover how immunotherapy is becoming a new standard of care for MSI-H/dMMR metastatic CRC.
View all episodes
By OncologyResearchExplore the latest breakthroughs in treating MSI-H/dMMR metastatic colorectal cancer with immune therapies! This episode dives into the exciting world of immune checkpoint inhibitors (ICIs) like nivolumab (Opdivo) and ipilimumab (Yervoy), highlighting their significant clinical benefits for this specific patient population. Learn about the molecular characteristics of MSI-H/dMMR CRC that make it uniquely sensitive to immunotherapy. Our AI hosts will cover pivotal clinical trials, including CheckMate 8HW, which demonstrated the improved progression-free survival with the combination of nivolumab and ipilimumab compared to nivolumab alone. Discover how immunotherapy is becoming a new standard of care for MSI-H/dMMR metastatic CRC.